Western Gas Equity Partners, LP (NYSE:WGP) shares decreased -4.16% in last trading session and ended the day at $38.26. WGP Gross Margin is 65.10% and its has a return on assets of 4.60%. Western Gas Equity Partners, LP (NYSE:WGP) quarterly performance is -23.13%.
Atlantic Tele-Network, Inc. (NASDAQ:ATNI) ended the last trading day at $79.91. Company weekly volatility is calculated as 2.57% and price to cash ratio as 3.23. Atlantic Tele-Network, Inc. (NASDAQ:ATNI) showed a weekly performance of 3.83%.
Zacks upgraded shares of Atlantic Tele-Network (NASDAQ:ATNI) from a hold rating to a buy rating in a report issued on Monday, MarketBeat.com reports. Zacks currently has $87.00 price target on the stock.
On 20 November, Onvia Inc. (NASDAQ:ONVI) shares moved up 3.05% and was closed at $3.94. ONVI EPS growth in last 5 year was -7.40%. Onvia Inc. (NASDAQ:ONVI) year to date (YTD) performance is -21.59%.
On 11 November, Onvia (NASDAQ:ONVI), announced the appointment of Steve Ritchie to the company’s executive management team as Senior Vice President of Sales.
Plum Creek Timber Co. Inc. (NYSE:PCL) shares moved up 0.80% in last trading session and ended the day at $50.41. PCL Gross Margin is 31.40% and its has a return on assets of 4.50%. Plum Creek Timber Co. Inc. (NYSE:PCL) quarterly performance is 27.62%.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Plum Creek Timber Co. Inc. (NYSE:PCL) (“PCL” or the “Company”) relating to the proposed buyout of the Company by Weyerhaeuser Company.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) caters to the Healthcare space. It has a net profit margin of -34.70% and weekly performance is -9.72%. On the last day of trading company shares ended up at $97.00. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) distance from 50-day simple moving average (SMA50) is 2.51%.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in comparable patients across three randomized, placebo-controlled studies that were conducted contemporaneously. Kyndrisa is currently under review with U.S. and European health authorities for the treatment of patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. This analysis is included in materials prepared by BioMarin for the November 24, 2015 Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) meeting.
Leave a Reply